Enclosed herewith Newspaper Advertisement
Enclosed herewith Annual Secretarial Compliance Report for the Year Ended March 31, 2026.
Enclosed herewith appointment of Chief Financial Officer, Tax Auditor, Internal Auditor and Reappointment of Cost Auditor.
Enclosed herewith Financial Results for the year ended March 31, 2026
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at their meeting held today i.e., May 29, 2026 inter-alia, considered the matters as enclosed herewith.
Auro Laboratories Limited has submitted the Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for Resignation of Mr. Kuntal Pancholi as the Chief Financial Officer & Key Managerial Personnel of the Company w.e.f May 28, 2026.
Audited Financial Results of the Company along with Report of the Auditors for the Quarter and Year Ended March 31, 2026 and any other matter with the permission of the Chair.
Auro Laboratories Limited submits that the Company has received a "Certification of Substances Department" from the European Directorate for the Quality of Medicines & Healthcare ("EDQM") for the Company's Manufacturing facility situated at M.I.D.C Tarapur, Maharashtra.
Auro Laboratories Limited submits that the Company has received a 'Certificate of GMP Compliance of a Manufacturer' from Swissmedic Swiss Agency for Therapeutic Products for the Company's manufacturing facility situated at M.I.D.C Tarapur, Maharashtra.
Auro Laboratories Limited has submitted the Disclosure in relation to Credit Rating obtained by the Company from Acuite Ratings & Research Limited.